Tisdag 18 November | 20:46:18 Europe / Stockholm

Svenska | English

Oculis Holding

Beskrivning

Land	Schweiz
Lista	Mid Cap Iceland
Sektor	Hälsovård
Industri	Bioteknik

Oculis Holding är specialiserade inom bioteknik. Bolaget bedriver forskning och utveckling inom topikala behandlingar för ögonsjukdomar. Exempel på specialistområden inkluderar diabetiskt makulaödem, bahandlingar för torra ögon och akut optisk neurit. Störst verksamhet återfinns inom Europa, där forskning bedrivs i egen regi men även via samarbetspartners. Bolaget har sitt huvudkontor i Zug, Schweiz.

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Filter

År

Typ

Språk

Rensa

2025-11-10 22:05:00 Oculis Reports Q3 2025 Financial Results and Provides Company Update 2450,00 ISK | +0,41% | 106 MISK

2025-11-10 22:05:00 Oculis birtir uppgjör fyrir þriðja ársfjórðung 2025 og kynnir áfanga í rekstri félagsins 2450,00 ISK | +0,41% | 106 MISK

2025-11-10 22:05:00 Oculis Reports Q3 2025 Financial Results and Provides Company Update 2450,00 ISK | +0,41% | 106 MISK

2025-11-05 10:00:00 Oculis to Participate in Upcoming November Investor Conferences 2450,00 ISK | +1,03% | 45,4 MISK

2025-10-30 09:30:44 Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development 2550,00 ISK | -3,04% | 1 478 MISK

2025-10-30 09:17:40 Oculis greinir frá umframeftirspurn í 110 milljóna USD fjármögnun sem er ætlað til að hraða klínískri þróun Privosegtor 2550,00 ISK | -3,04% | 1 478 MISK

2025-10-30 09:17:40 Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development 2550,00 ISK | -3,04% | 1 478 MISK

2025-10-14 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2600,00 ISK | +0,39% | 350 MISK

2025-10-14 10:00:00 Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025 2590,00 ISK | +0,19% | 19,1 MISK

2025-10-08 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2530,00 ISK | +5,42% | 611 MISK

2025-10-06 10:07:00 Oculis hrindir af stað skráningarrannsóknum á Privosegtor við bráðri sjóntaugabólgu, sem gæti orðið fyrsta taugaverndandi meðferð sinnar tegundar 2190,00 ISK | +3,79% | 63,2 MISK

2025-10-06 10:07:00 Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy 2190,00 ISK | +3,79% | 63,2 MISK

2025-09-26 22:05:00 Oculis Publishes Notification of Transactions by Person Discharging Managerial Responsibilities

2025-09-22 10:00:00 Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS 2050,00 ISK | -1,44% | 43,9 MISK

2025-09-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2090,00 ISK | +1,46% | 18,1 MISK

2025-09-04 19:00:00 Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025 2080,00 ISK | +1,96% | 58,1 MISK

2025-09-03 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2040,00 ISK | +2,00% | 450 MISK

2025-09-01 10:00:00 Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences 1990,00 ISK | 0,00% | 4,79 MISK

2025-08-28 10:00:00 Oculis to Participate in Upcoming September Investor Conferences 2080,00 ISK | -2,35% | 63,9 MISK

2025-08-25 10:00:00 Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors 2170,00 ISK | -0,23% | 268 MISK

2025-08-21 22:05:00 Oculis Reports Q2 2025 Financial Results and Provides Company Update 2175,00 ISK | +0,23% | 11,5 MISK

2025-08-21 22:05:00 Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri félagsins 2175,00 ISK | +0,23% | 11,5 MISK

2025-08-12 10:00:00 Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference 2240,00 ISK | -0,44% | 3,43 MISK

2025-08-12 10:00:00 Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtual Conference 2240,00 ISK | -0,44% | 3,43 MISK

2025-08-01 10:00:00 Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF 2180,00 ISK | +0,46% | 0,46 MISK

2025-08-01 10:00:00 Oculis Upsized Loan Facility to Access up to CHF 100 million 2180,00 ISK | +0,46% | 0,46 MISK

2025-07-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2250,00 ISK | -0,88% | 32,0 MISK

2025-06-09 22:05:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2510,00 ISK | -1,18% | 16,3 MISK

2025-06-05 10:00:00 Oculis Publishes Results of 2025 Annual General Meeting 2450,00 ISK | +2,08% | 309 MISK

2025-06-05 10:00:00 Oculis birtir niðurstöður aðalfundar 2025 2450,00 ISK | +2,08% | 309 MISK

2025-06-05 10:00:00 Oculis Publishes Results of 2025 Annual General Meeting 2450,00 ISK | +2,08% | 309 MISK

2025-06-03 23:00:00 Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities 2400,00 ISK | -0,83% | 116 MISK

2025-06-03 10:00:00 Oculis to Participate in Upcoming June Investor Conferences 2420,00 ISK | -1,22% | 61,2 MISK

2025-05-09 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 2470,00 ISK | +2,49%

2025-05-09 22:05:00 Oculis birtir boð á aðalfund 2470,00 ISK | +2,49%

2025-05-09 22:05:00 Oculis Publishes Invitation to the Annual General Meeting 2470,00 ISK | +2,49%

2025-05-07 10:00:00 Oculis to Present at Upcoming May Investor Conferences 2320,00 ISK | -2,52% | 75,3 MISK

Visa fler

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oculis Holding

Beskrivning

Vem äger bolaget?

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden